NovoCure Ltd.
366 articles about NovoCure Ltd.
-
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
3/11/2024
Novocure announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology 2024 Congress in Barcelona.
-
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
2/22/2024
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.
-
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
1/18/2024
Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA).
-
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
1/9/2024
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio ® (formerly known as Optune ® ) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM).
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
1/8/2024
Novocure reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023.
-
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
1/4/2024
Novocure announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.
-
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
12/27/2023
Novocure announced that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024.
-
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
11/28/2023
Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation.
-
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
11/21/2023
Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.
-
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
11/10/2023
Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada.
-
Novocure Reports Third Quarter 2023 Financial Results
10/26/2023
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023.
-
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
10/15/2023
Novocure announced its participation in the European Society for Medical Oncology Congress 2023 from October 20 – 24 in Madrid.
-
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
10/12/2023
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
-
Novocure to Report Third Quarter 2023 Financial Results
10/2/2023
Novocure announced that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open.
-
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
9/29/2023
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.
-
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
9/8/2023
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.
-
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
8/29/2023
Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology.
-
The company’s investigational electric field therapy was unable to elicit significant survival benefits in patients with platinum-resistant ovarian cancer.
-
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
8/28/2023
Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis.
-
Novocure to Participate in Upcoming September 2023 Investor Conferences
8/25/2023
Novocure announced that management will participate in two upcoming investor conferences.